Swedish biotech firm Alligator Bioscience (STO: ATORX) has appointed Anu Balendran, as vice president business development.
Dr Balendran will be responsible for leading Alligator’s preclinical projects towards out-licensing. He has a PhD in Biochemistry and will join Alligator from his current role as external innovation director at Anglo-Swedish pharma major AstraZeneca (LSE: AZ). He will assume his new role on May 1, 2018.
This appointment follows those of Charlotte A Russell, as chief medical officer and Peter Ellmark, as vice president discovery, in December 2017, as Alligator prepares a number of drug candidates for clinical studies, partnerships and licensing deals.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze